T
Tarsa Therapeutics
Develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis
About Tarsa Therapeutics
Tarsa Therapeutics is a biopharmaceutical company specializing in the development of novel treatments for postmenopausal osteoporosis. The company has developed an innovative oral formulation of calcitonin, a natural hormone with a long history of safety and efficacy in treating osteoporosis. This product, known as TBRIA, is designed for women more than five years post-menopause who cannot use alternative treatments. Tarsa Therapeutics operates in the healthcare and pharmaceutical market, targeting a niche segment of postmenopausal women with specific medical needs. The business model revolves around the development, clinical testing, and eventual commercialization of their proprietary oral calcitonin formulation. Revenue is generated through licensing agreements, partnerships, and potential sales of the approved treatment. TBRIA has demonstrated positive safety and efficacy in the global, randomized, double-blind Phase 3 ORACAL trial, showing statistical superiority to both placebo and nasal calcitonin spray in increasing bone mineral density at the lumbar spine after 48 weeks of use. The safety profile of TBRIA did not substantially differ from nasal calcitonin or placebo.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Philadelphia, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 24.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Oncology, DNA, Genetics and genomics, Orthopedic, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jul 2016 | $1.2M | — | Square 1 Bank · Oxford Finance | — |
| DEBTDebt | Feb 2016 | $2M | — | Square 1 Bank · Oxford Finance | — |
Growth signals
Latest recorded traffic for Tarsa Therapeutics is 260 monthly website visits, up 550% over the last three months. Tarsa Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tarsa Therapeutics in the Philadelphia ecosystem
The Tarsa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Novo Ventures
MVM Life Science Partners
Foresite Capital
Series B and later2 investors entered at this stage
Square 1 Bank
Oxford Finance
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tarsa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tarsa Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








